Seeking Alpha

More on Actavis Q4: Warner Chilcott boosts revenue

  • Actavis (ACT +0.7%) swings to a loss of $148.4M from a profit of $28M a year earlier, with earnings hurt by restructuring-related expenses and other items.
  • EBITDA jumps to $817.1M from $393M, boosted by the acquisition of Warner Chilcott.
  • Pharma Segment revenue $1.7B vs $1.4B; Specialty Brands $695.5M vs $132.2M; Anda Distribution $383M vs $203.9M.
  • Actavis intends to provide updated 2014 guidance after it closes the $25B acquisition of Forest Labs.
  • The company affirms its forecasts for Actavis alone: it expects EPS of $12.60-13.10 vs consensus of $12.99, and revenues of over $10B vs $10.86B. (PR)
  • Previous
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: